MX2010004549A - Composiciones y métodos bacteriostáticos o bactericidas. - Google Patents

Composiciones y métodos bacteriostáticos o bactericidas.

Info

Publication number
MX2010004549A
MX2010004549A MX2010004549A MX2010004549A MX2010004549A MX 2010004549 A MX2010004549 A MX 2010004549A MX 2010004549 A MX2010004549 A MX 2010004549A MX 2010004549 A MX2010004549 A MX 2010004549A MX 2010004549 A MX2010004549 A MX 2010004549A
Authority
MX
Mexico
Prior art keywords
bacterial infection
enriched
methods
fluids
gas
Prior art date
Application number
MX2010004549A
Other languages
English (en)
Spanish (es)
Inventor
Anthony B Wood
Richard L Watson
Gregory J Archambeau
Original Assignee
Revalesio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2007/082578 external-priority patent/WO2008052143A2/en
Priority claimed from PCT/US2007/082580 external-priority patent/WO2008052145A2/en
Priority claimed from PCT/US2007/082581 external-priority patent/WO2008115290A2/en
Application filed by Revalesio Corp filed Critical Revalesio Corp
Publication of MX2010004549A publication Critical patent/MX2010004549A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2010004549A 2007-10-25 2008-10-23 Composiciones y métodos bacteriostáticos o bactericidas. MX2010004549A (es)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US98272007P 2007-10-25 2007-10-25
US98271907P 2007-10-25 2007-10-25
PCT/US2007/082578 WO2008052143A2 (en) 2006-10-25 2007-10-25 Mixing device and output fluids of same
PCT/US2007/082580 WO2008052145A2 (en) 2006-10-25 2007-10-25 Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
PCT/US2007/082581 WO2008115290A2 (en) 2006-10-25 2007-10-25 Methods of wound care and treatment
US4833208P 2008-04-28 2008-04-28
US4840408P 2008-04-28 2008-04-28
US4834008P 2008-04-28 2008-04-28
US4834708P 2008-04-28 2008-04-28
US4841608P 2008-04-28 2008-04-28
PCT/US2008/081029 WO2009055620A1 (en) 2007-10-25 2008-10-23 Bacteriostatic or bacteriocidal compositions and methods

Publications (1)

Publication Number Publication Date
MX2010004549A true MX2010004549A (es) 2010-07-28

Family

ID=42238385

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004549A MX2010004549A (es) 2007-10-25 2008-10-23 Composiciones y métodos bacteriostáticos o bactericidas.

Country Status (8)

Country Link
EP (2) EP2207669A4 (https=)
JP (3) JP5586470B2 (https=)
CN (3) CN101909869B (https=)
AU (2) AU2008316708A1 (https=)
CA (2) CA2703648A1 (https=)
IL (2) IL205321A0 (https=)
MX (1) MX2010004549A (https=)
WO (1) WO2009055620A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
US8597689B2 (en) 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
AU2007308838B2 (en) 2006-10-25 2014-03-13 Revalesio Corporation Mixing device and output fluids of same
MX2010004549A (es) * 2007-10-25 2010-07-28 Revalesio Corp Composiciones y métodos bacteriostáticos o bactericidas.
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
EP2215260A4 (en) * 2007-10-25 2011-04-20 Revalesio Corp COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US8980325B2 (en) 2008-05-01 2015-03-17 Revalesio Corporation Compositions and methods for treating digestive disorders
US8399006B2 (en) 2009-01-29 2013-03-19 Forsight Vision4, Inc. Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
BR112012028540A2 (pt) 2010-05-07 2016-07-26 Revalesio Corp composições e métodos para melhorar desempenho fisiológico e tempo de recuperação
EP3861969A1 (en) 2010-08-05 2021-08-11 ForSight Vision4, Inc. Injector apparatus for drug delivery
JP6111194B2 (ja) 2010-08-05 2017-04-05 フォーサイト・ビジョン フォー・インコーポレーテッド 組み合わせ薬物送達方法および装置
SI2600812T1 (sl) 2010-08-05 2021-12-31 ForSight Vision4, Inc., Naprava za zdravljenje očesa
JP2013533320A (ja) 2010-08-12 2013-08-22 レバレジオ コーポレイション タウオパチーを治療するための組成物および方法
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP4249059B1 (en) 2011-06-28 2025-07-30 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
RS61758B1 (sr) 2011-09-16 2021-05-31 Forsight Vision4 Inc Aparati za razmenu tečnosti
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
JP6159584B2 (ja) * 2012-06-14 2017-07-05 松本　高明 輸液、輸液の製造方法および輸液装置
CA2905496A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
ES2972168T3 (es) 2013-03-28 2024-06-11 Forsight Vision4 Inc Implante oftálmico para administración de sustancias terapéuticas
GB201402513D0 (en) * 2014-02-13 2014-04-02 Cardiff Scintigraphics Ltd Pressurised metered dose inhalers and method of manufacture
KR101930573B1 (ko) * 2014-04-23 2018-12-18 주식회사 티씨엠생명과학 세포 도말 장치 및 세포 도말 방법
EP3169289B1 (en) 2014-07-15 2020-04-15 ForSight Vision4, Inc. Ocular implant delivery device
BR112017002466A2 (pt) 2014-08-08 2017-12-05 Forsight Vision4 Inc formulações estáveis e solúveis de inibidores da tirosina cinase do receptor, e métodos para a sua preparação
WO2016077371A1 (en) 2014-11-10 2016-05-19 Forsight Vision4, Inc. Expandable drug delivery devices and method of use
CA3005238A1 (en) 2015-11-20 2017-05-26 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
JP7009384B2 (ja) 2016-04-05 2022-01-25 フォーサイト・ビジョン フォー・インコーポレーテッド 移植可能な眼薬送達デバイス
JP7287888B2 (ja) * 2016-06-27 2023-06-06 ギャラリー，インコーポレイテッド ジェネレータ、電極付きのカテーテル、及び肺通路の治療方法
KR20200093581A (ko) 2017-11-21 2020-08-05 포사이트 비젼4, 인크. 확장 가능한 포트 전달 시스템을 위한 유체 교환 기기 및 사용 방법
US11759677B2 (en) 2018-02-16 2023-09-19 University Of Louisville Research Foundation, Inc. Respiratory training and airway pressure monitoring device
KR102171489B1 (ko) * 2018-10-30 2020-10-29 (주)메가메디칼 네블라이저 및 산소공급기가 구비되는 네블라이저 장치
EP4125847A4 (en) * 2020-04-03 2024-06-19 Lpoxy Therapeutics, Inc. ENTERAL AEROBIZATION THERAPY
US20230210848A1 (en) * 2020-04-30 2023-07-06 Fujifilm Toyama Chemical Co., Ltd. Coronavirus infection therapeutic agent formed through combination of pyrazine derivative and another coronavirus infection therapeutic drug
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1157720A (ja) * 1996-11-07 1999-03-02 Honda Motor Co Ltd 電解機能水、その製造方法及び製造装置
US7654728B2 (en) * 1997-10-24 2010-02-02 Revalesio Corporation System and method for therapeutic application of dissolved oxygen
IL124788A (en) * 1998-06-07 1999-04-11 Ben Hador David Boomerang launcher
US6477410B1 (en) * 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
US20060198901A9 (en) * 1999-10-26 2006-09-07 Holloway William D Jr Drugs, bio-affecting and body treating compositions
EP1237578A4 (en) * 1999-10-26 2004-10-27 Bio Hydration Res Lab Inc MICRO-AGGREGATED LIQUIDS AND METHODS OF MAKING AND USING SAME
US6426066B1 (en) * 2000-01-12 2002-07-30 California Pacific Labs, Inc. Use of physiologically balanced, ionized, acidic solution in wound healing
JP4064671B2 (ja) * 2000-02-25 2008-03-19 エフ．ホフマン−ラ ロシュ アーゲー アデノシン受容体モジュレーター
EP1357920B1 (en) * 2001-02-01 2007-09-05 Hydron Technologies Inc. Compositions and method of tissue superoxygenation
US20030199089A1 (en) * 2001-06-05 2003-10-23 Surber Mark W. Membrane to membrane delivery
US20030232114A1 (en) * 2002-06-13 2003-12-18 Nikola Dekleva Method for liquid enrichment with oxygen and applications of enriched liquids
AU2002321678A1 (en) * 2002-09-09 2004-03-29 Boros Béla Oxygen-enriched water, treated within a magnetic field and heavy water
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
ATE500234T1 (de) * 2003-11-10 2011-03-15 Merck Sharp & Dohme Substituierte trialzole als blocker des natriumkanals
JP4144669B2 (ja) * 2004-03-05 2008-09-03 独立行政法人産業技術総合研究所 ナノバブルの製造方法
US20060073212A1 (en) * 2004-04-22 2006-04-06 Palmer Craig R Method of treating respiratory disorders and airway inflammation
CA2574848A1 (en) * 2004-08-05 2006-12-21 Wyeth Antagonizing interleukin-21 receptor activity
US20060273016A1 (en) * 2005-06-03 2006-12-07 BAGLEY David Method for preparing water with a stable negative oxidation reduction potential (ORP)
WO2008018932A2 (en) * 2006-05-01 2008-02-14 The Board Of Trustees Of The Leland Stanford Junior University Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
AU2007308838B2 (en) * 2006-10-25 2014-03-13 Revalesio Corporation Mixing device and output fluids of same
JP5491185B2 (ja) * 2006-10-25 2014-05-14 リバルシオ コーポレイション 傷のケアおよび処置の方法
EP2215260A4 (en) * 2007-10-25 2011-04-20 Revalesio Corp COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION
MX2010004549A (es) * 2007-10-25 2010-07-28 Revalesio Corp Composiciones y métodos bacteriostáticos o bactericidas.
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
JP2011050844A (ja) * 2009-09-01 2011-03-17 Kurita Water Ind Ltd 電気浸透脱水方法及び装置

Also Published As

Publication number Publication date
JP5750540B2 (ja) 2015-07-22
WO2009055620A1 (en) 2009-04-30
AU2008316556B2 (en) 2014-12-18
JP5647897B2 (ja) 2015-01-07
CN103721258B (zh) 2015-12-09
IL205320A0 (en) 2010-12-30
EP2214712A4 (en) 2013-02-27
EP2207669A4 (en) 2011-11-02
CA2703714A1 (en) 2009-04-30
CN101909869A (zh) 2010-12-08
EP2214712A1 (en) 2010-08-11
AU2008316708A1 (en) 2009-04-30
IL205320A (en) 2017-03-30
CN101909869B (zh) 2014-12-17
JP2011500838A (ja) 2011-01-06
JP2015028087A (ja) 2015-02-12
CA2703648A1 (en) 2009-04-30
CN101909649A (zh) 2010-12-08
IL205321A0 (en) 2010-12-30
JP5586470B2 (ja) 2014-09-10
EP2214712B1 (en) 2016-05-18
AU2008316556A1 (en) 2009-04-30
JP2011500854A (ja) 2011-01-06
EP2207669A1 (en) 2010-07-21
CN101909649B (zh) 2014-01-29
CN103721258A (zh) 2014-04-16

Similar Documents

Publication Publication Date Title
MX2010004549A (es) Composiciones y métodos bacteriostáticos o bactericidas.
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
MY143795A (en) Tetrahydropyridoindole derivatives
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
ATE360631T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
WO2005037199A3 (en) Pyrazole derivatives as cannabinoid receptor modulators
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
SE0401342D0 (sv) Therapeutic compounds
TW200716628A (en) Novel compounds
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
TNSN08321A1 (en) Dimers of artemisinin derivatives, preparation thereof and therapeutic use thereof
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
TW200727903A (en) Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate
TW200504030A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
ATE531703T1 (de) Benzochromenderivate
MX2007009312A (es) Preparaciones inyectables de diclofenaco y sus sales farmaceuticamente aceptables.
TW200715961A (en) Herbicide composition

Legal Events

Date Code Title Description
FG Grant or registration